Drugs, Pregnancy & Lactation

Breastfeeding with the FDA’s novel drugs approved in 2017, and others


 

Gastrointestinal

Plecanatide (Trulance) (MW 1.7 kg/mol). Diarrhea.

Telotristat (Xermelo) (MW 574 g/mol). Nausea, headache, increased gamma-glutamyltransferase, depression, flatulence, decreased appetite, peripheral edema, pyrexia.

Hematologic

Betrixaban (Bevyxxa) (MW 568 g/mol). Bleeding.

Emicizumab (Hemlibra) (MW 145.6 kg/mol). Headache, arthralgia.

Immunologic

Sarilumab (Kevzara) (MW 150 kg/mol). Neutropenia, increased ALT, upper respiratory infections, urinary tract infections.

Ophthalmic

Latanoprostene bunod (Vyzulta) (MW 508 g/mol). All related to the eye.

Netarsudil (Rhopressa) (MW 454 g/mol). All related to the eye.

Parathyroid hormone

Abaloparatide (Tymlos) (MW 3.9 kg/mol). Hypercalciuria, dizziness, nausea, headache, palpitations, fatigue, upper abdominal pain, vertigo.

Respiratory

Benralizumab (Fasenra) (MW 150 kg/mol). Headache, pharyngitis.

Pages

Recommended Reading

Pregnancy may be ideal time to consider switching MS drugs
MDedge ObGyn
What do the genes GDF15 and IGFBP7 mean for the future of hyperemesis gravidarum treatment?
MDedge ObGyn
Supreme Court case NIFLA v Becerra: What you need to know
MDedge ObGyn
Mifepristone, then misoprostol is best in early pregnancy loss
MDedge ObGyn
No link found between fluconazole use and neonatal death risk
MDedge ObGyn
NIH launches HEAL Initiative to combat opioid crisis
MDedge ObGyn
Thyroid markers linked to risk of gestational diabetes
MDedge ObGyn
Yale meeting draws cadre of physician-scientists
MDedge ObGyn
How better imaging technology for prenatal diagnoses can improve outcomes
MDedge ObGyn
How congenital heart disease affects brain development
MDedge ObGyn